Close Menu

financial results

The company's revenue growth was driven in part by a US copromotion alliance for Janssen Biotech's rheumatoid arthritis drug Simponi.

For FY 2019, the firm's revenues dropped 11 percent to $19.2 million from $21.5 million in 2018, matching analysts' expectations. 

Q4 Revenue growth was driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.

The company reported a net loss of $8.0 million, or $.15 per share, as it saw increased costs associated with its transition to commercial test provision.

OpGen also reported full-year growth was driven by revenue increases for its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.

The company' theranostics revenue were up 10 percent while its IVD revenues grew 6 percent. It posted a profit of €349,000 for 2019.

The firm appointed Richard Eberly, formerly a managing director at private equity firm Solid Rock Principled Capital, as CEO.

The La Jolla, California-based developer of genomic melanoma tests posted nearly $1.6 million in revenues in Q4, up from $600,000 in Q4 2018. 

The skin cancer diagnostics company said it delivered 37 percent more DecisionDx-Melanoma test results in Q4 2019 than in the previous year's fourth quarter.

The firm reported quarterly revenues of $8.4 million and large increases in the number of billable tests delivered in the quarter and over the full year.

Pages